Ladostigil Explained

Ladostigil (developmental code name TV-3326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease.[1] [2] It was developed from structural modification of rasagiline.[3]

The drug acts as a reversible acetylcholinesterase and butyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule.[4] [5] In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis.[6] Ladostigil also has antidepressant-like effects in animals, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.[7] [8]

There have been no new updates on the pharmaceutical development of ladostigil since 2019. At this time, it was in phase 2 clinical trials for Alzheimer's disease.

See also

Notes and References

  1. Web site: Ladostigil - Avraham Pharmaceuticals . AdisInsight . 3 August 2022 . 17 August 2024.
  2. Book: Weinstock M, Bejar C, Wang RH, etal . TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease . Advances in Research on Neurodegeneration . Journal of Neural Transmission. Supplementum . 60 . 157–69 . 2000 . 10.1007/978-3-7091-6301-6_10 . 11205137 . 978-3-211-83537-1 .
  3. Chen JJ, Swope DM . Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease . Journal of Clinical Pharmacology . 45 . 8 . 878–894 . August 2005 . 16027398 . 10.1177/0091270005277935 . dead . 24350277 . https://archive.today/20120711214831/http://jcp.sagepub.com/cgi/pmidlookup?view=long&pmid=16027398 . 11 July 2012 .
  4. Weinreb O, Mandel S, Bar-Am O, etal . Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs . Neurotherapeutics . 6 . 1 . 163–74 . January 2009 . 19110207 . 10.1016/j.nurt.2008.10.030 . 5084264 .
  5. Book: Weinstock M, Luques L, Bejar C, Shoham S . Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression . Parkinson's Disease and Related Disorders . Journal of Neural Transmission. Supplementum . 70 . 443–6 . 2006 . 10.1007/978-3-211-45295-0_67 . 17017566 . 978-3-211-28927-3 .
  6. Weinreb O, Amit T, Bar-Am O, Youdim MB . Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy . Annals of the New York Academy of Sciences . 1122 . 155–68 . December 2007 . 1 . 18077571 . 10.1196/annals.1403.011 . 2007NYASA1122..155W . 39753711 .
  7. Weinstock M, Poltyrev T, Bejar C, Youdim MB . Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression . Psychopharmacology . 160 . 3 . 318–24 . March 2002 . 11889501 . 10.1007/s00213-001-0978-x . 26001621 .
  8. Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M . A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease . Progress in Neuro-psychopharmacology & Biological Psychiatry . 27 . 4 . 555–61 . June 2003 . 12787840 . 10.1016/S0278-5846(03)00053-8 . 21612561 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ladostigil".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.